Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00417833|
Recruitment Status : Completed
First Posted : January 4, 2007
Last Update Posted : October 20, 2008
Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).
Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Proliferative Retinopathy Vascular Vein Oclussion Choroidal Neovascularization||Drug: Intravitreal Bevacizumab||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||December 2005|
|Study Completion Date :||July 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00417833
|Principal Investigator:||Myrian L Hernández, MD||Asociación para Evitar la Ceguera en México|